Pneumocystis jiroveci pneumonia in relation to CD4 lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy

Leukemia and Lymphoma

Volumn 51, Issue 10, 2010, Pages 1816-1821

  Hashimoto, Kenji ^a   Kobayashi, Yukio ^a   Asakura, Yoshitaka ^a   Mori, Masakazu ^a   Azuma, Teruhisa ^a   Maruyama, Dai ^a   Kim, Sung Won ^a   Watanabe, Takashi ^a   Tobinai, Kensei ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

B cell non Hodgkin lymphoma; CD4+ lymphocyte; chemotherapy; Pneumocystis jiroveci pneumonia; prophylaxis; rituximab

Indexed keywords

CHLORMETHINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; SULFAMETHOXAZOLE; TRIMETHOPRIM; VINCRISTINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; YOUNG ADULT;

EID: 77957735401     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.506569     Document Type: Article

References (20)

1. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-2498.
2. Kovacs JA, Masur H. Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immunodefi-ciencyvirus. Clin Infect Dis 1992;14:1005-1009.
3. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007;92:139-140.
4. Browne MJ, Hubbard SM, Longo DL, et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med 1986;104:338-344.
5. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classifica-tion oftumours. Lyon: IARC Press; 2001.
6. Mead GM, Sydes MR, Walewski J, et al. UKLG LY06 collaborators. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lympho-ma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002;13:1264-1274.
7. Glick JH, Barnes JM, Ezdinli EZ, Berard CW, Orlow EL, Bennett JM. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981;58: 920-925.
8. Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009;135:655-661.
9. Marty FM, Koo S, Bryar J, Baden LR. (1-7gt;3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007;147:70-72.
10. Wilkin A, Feinberg J. Pneumocystis carinii pneumonia: a clinical review. Am Fam Physician 1999;60:1699-1708, 1713-1714.
11. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010;51:797-801.
12. Tadmor T, McLaughlin P, Polliack A. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? Leuk Lymphoma 2010;51:737-738.
13. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimens for indolent lymphoma. J Clin Oncol 1996;14:1262-1268.
14. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
15. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007;109:2182-2189.
16. Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J. Interstitial pneumonitis during rituximab-containing che-motherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2008;49:1778-1783.
17. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916-919.
18. Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence ofinterstitial pneumonia by CHOP combined with rituximab. Int J Hematol 2008;87:393-397.
19. Katsuya H, SuzumiyaJ, Sasaki H, et al. Addition ofrituximab to cyclophosphamide, doxorubicin, vincristine, and predniso-lone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:1818-1823.
20. Laszlo D, Bassi S, And reola G, et al. Peripheral T-lymphocyte subsets in patients treated with rituximab-chlorambucil combination therapy for indolent NHL. Ann Hematol 2006; 85:813-814.